H

hVIVO Services Limited | Queen Mary BioEnterprises Innovation Centre

Research site

(Unclaimed)

Location

42 New Road, London, London, City of, England

Site insights

Top conditions

Top treatments

Neumifil

CC-42344

JNJ-64281802

EDP-323

JNJ-64417184

Palivizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 12 total trials

A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

A randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of o...

Enrolling

RSV Infection

Drug: EDP-323 Dose Regimen 1

Drug: Placebo

Influenza Viral Challenge Study of CC-42344 in Healthy Participants

Participants in this study will be given either CC-42344 (one of two dose levels) or placebo orally for 5 days after receiving an influenza (flu) cha...

Enrolling

Influenza A

Drug: Placebo

Drug: CC-42344